These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17944931)

  • 1. CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages.
    Dace DS; Chen PW; Niederkorn JY
    Immunology; 2008 Mar; 123(3):367-77. PubMed ID: 17944931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
    Dace DS; Chen PW; Alizadeh H; Niederkorn JY
    J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD8+ T cells circumvent immune privilege in the eye and mediate intraocular tumor rejection by a TNF-alpha-dependent mechanism.
    Dace DS; Chen PW; Niederkorn JY
    J Immunol; 2007 May; 178(10):6115-22. PubMed ID: 17475837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IFN-γ-independent intraocular tumor rejection is mediated by a macrophage-dependent process that leaves the eye intact.
    Coursey TG; Chen PW; Niederkorn JY
    J Leukoc Biol; 2012 Nov; 92(5):939-50. PubMed ID: 22693246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of TRAIL and IFN-gamma in CD4+ T cell-dependent tumor rejection in the anterior chamber of the eye.
    Wang S; Boonman ZF; Li HC; He Y; Jager MJ; Toes RE; Niederkorn JY
    J Immunol; 2003 Sep; 171(6):2789-96. PubMed ID: 12960299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17-dependent, IFN-gamma-independent tumor rejection is mediated by cytotoxic T lymphocytes and occurs at extraocular sites, but is excluded from the eye.
    Coursey TG; Chen PW; Niederkorn JY
    J Immunol; 2011 Oct; 187(8):4219-28. PubMed ID: 21918192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of interferon-γ and cytotoxic T lymphocytes in intraocular tumor rejection.
    Ligocki AJ; Brown JR; Niederkorn JY
    J Leukoc Biol; 2016 May; 99(5):735-47. PubMed ID: 26578649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages are vital in spontaneous intraocular tumor eradication.
    Boonman ZF; Schurmans LR; van Rooijen N; Melief CJ; Toes RE; Jager MJ
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2959-65. PubMed ID: 16799039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogating TNF-α expression prevents bystander destruction of normal tissues during iNOS-mediated elimination of intraocular tumors.
    Coursey TG; Chen PW; Niederkorn JY
    Cancer Res; 2011 Apr; 71(7):2445-54. PubMed ID: 21307132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rejection of intraocular tumors by CD4(+) T cells without induction of phthisis.
    Schurmans LR; Diehl L; den Boer AT; Sutmuller RP; Boonman ZF; Medema JP; van der Voort EI; Laman J; Melief CJ; Jager MJ; Toes RE
    J Immunol; 2001 Nov; 167(10):5832-7. PubMed ID: 11698457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Killer T Cells Contribute to Neutrophil Recruitment and Ocular Tissue Damage in a Model of Intraocular Tumor Rejection.
    Ligocki AJ; Niederkorn JY
    Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):813-23. PubMed ID: 26934137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4+ T cells initiate pancreatic islet xenograft rejection via an interferon-gamma-dependent recruitment of macrophages and natural killer cells.
    Yi S; Feng X; Hawthorne WJ; Patel AT; Walters SN; O'Connell PJ
    Transplantation; 2002 Feb; 73(3):437-46. PubMed ID: 11884942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunopathology of intraocular tumour rejection.
    Niederkorn JY
    Eye (Lond); 1991; 5 ( Pt 2)():186-92. PubMed ID: 2070879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rejection of mouse melanoma elicited by local secretion of interleukin-2: implicating macrophages without T cells or natural killer cells in tumor rejection.
    Hara I; Nguyen H; Takechi Y; Gansbacher B; Chapman PB; Houghton AN
    Int J Cancer; 1995 Apr; 61(2):253-60. PubMed ID: 7705956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic evaluation of spontaneous regression of an intraocular murine melanoma.
    Knisely TL; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1990 Feb; 31(2):247-57. PubMed ID: 2154414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenectomy promotes indirect elimination of intraocular tumors by CD8+ T cells that is associated with IFNγ- and Fas/FasL-dependent activation of intratumoral macrophages.
    Miller MR; Mandell JB; Beatty KM; Harvey SA; Rizzo MJ; Previte DM; Thorne SH; McKenna KC
    Cancer Immunol Res; 2014 Dec; 2(12):1175-85. PubMed ID: 25248763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell-activated macrophages are capable of both recognition and rejection of pancreatic islet xenografts.
    Yi S; Hawthorne WJ; Lehnert AM; Ha H; Wong JK; van Rooijen N; Davey K; Patel AT; Walters SN; Chandra A; O'Connell PJ
    J Immunol; 2003 Mar; 170(5):2750-8. PubMed ID: 12594306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.
    Benson JL; Niederkorn JY
    Immunology; 1991 Sep; 74(1):153-9. PubMed ID: 1937568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.